Novartis India Limited AI Stock Analysis
Want to see IN:NOVARTIND full AI Analyst Report?
Novartis India Limited (NOVARTIND) AI Stock Analysis
Novartis India Limited
(NSE:NOVARTIND)
The score is primarily driven by the strong financial position from an exceptional balance sheet and healthy cash flows. Mixed technical indicators and a negative P/E ratio are the main limiting factors.
Novartis India Limited (NOVARTIND) vs. iShares MSCI India ETF (INDA)
- Market Cap
- INR 34.07B
- Dividend Yield
- 1.54%
- Average Volume (3M)
- 12.01K
- Price to Earnings (P/E)
- -862.5
- Beta (1Y)
- -0.15
- Revenue Growth
- -5.20%
- EPS Growth
- -103.74%
- Country
- India
- Employees
- 59
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
Novartis India Limited Business Overview & Revenue Model
Company Description
Evonile Pharma Limited, an affiliate of Novartis AG, operates as a healthcare enterprise primarily within India. The company's diverse portfolio encompasses a range of therapeutic solutions. These include bone and pain management treatments sold unde...
How the Company Makes Money
Novartis India Limited primarily makes money by commercializing pharmaceutical products in India. Its core revenue stream is the sale of branded prescription medicines to customers such as hospitals, pharmacies, distributors, and other healthcare cha...
Novartis India Limited Financial Statement Overview
Summary
Strong balance sheet with near-zero debt and robust cash flows support stability, though revenue declines have limited income statement performance.
Income Statement
64PositiveBalance Sheet
94Very PositiveCash Flow
79Positive| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.36B | 3.54B | 3.98B | 3.35B | 3.79B | 3.88B |
| Gross Profit | 1.04B | 1.33B | 1.53B | 1.32B | 1.77B | 2.06B |
| EBITDA | 548.20M | 941.00M | 1.33B | 652.60M | 1.23B | 106.60M |
| Net Income | -39.90M | 931.80M | 1.01B | 851.90M | 1.03B | -37.20M |
Balance Sheet | ||||||
| Total Assets | 22.78B | 9.78B | 9.48B | 9.25B | 9.83B | 9.58B |
| Cash, Cash Equivalents and Short-Term Investments | 3.03B | 6.68B | 6.37B | 5.85B | 5.70B | 5.16B |
| Total Debt | 7.96B | 32.10M | 50.60M | 69.70M | 215.10M | 240.10M |
| Total Liabilities | 15.06B | 1.60B | 1.63B | 1.80B | 2.07B | 2.66B |
| Stockholders Equity | 7.72B | 8.18B | 7.85B | 7.45B | 7.76B | 6.92B |
Cash Flow | ||||||
| Free Cash Flow | 0 | 843.60M | 745.70M | 1.48B | 444.90M | 381.70M |
| Operating Cash Flow | 0 | 847.00M | 745.70M | 1.13B | 448.00M | 386.70M |
| Investing Cash Flow | 0 | -203.40M | -33.10M | 331.30M | -1.53B | 870.40M |
| Financing Cash Flow | 0 | -639.30M | -641.50M | -1.21B | -304.80M | -356.30M |
Novartis India Limited Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:NOVARTIND, the sentiment is Negative. The current price of 1368.25 is below the 20-day moving average (MA) of 1487.15, below the 50-day MA of 1607.02, and above the 200-day MA of 1185.13, indicating a neutral trend. The MACD of -39.88 indicates Positive momentum. The RSI at 35.89 is Neutral, neither overbought nor oversold. The STOCH value of 9.41 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:NOVARTIND.
Novartis India Limited Peers Comparison
Overall Rating
IN:CIPLA73Outperform
IN:NOVARTIND68Neutral
IN:LUPIN67Neutral
IN:GLENMARK66Neutral
IN:DRREDDY62Neutral
IN:ASTRAZEN59Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 73Outperform | INR 1.14T | 39.45 | ― | 2.05% | -0.74% | -46.77% | |
| 68Neutral | INR 47.86B | -862.50 | ― | 1.54% | -5.20% | -103.74% | |
| 67Neutral | INR 919.16B | 17.68 | ― | 0.90% | 24.22% | 20.24% | |
| 66Neutral | INR 747.33B | 51.49 | ― | 0.19% | -0.11% | 43.72% | |
| 62Neutral | INR 1.16T | 41.38 | ― | 0.58% | -3.60% | -52.23% | |
| 59Neutral | INR 153.96B | 86.76 | ― | 0.58% | 29.70% | -10.76% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IN:NOVARTIND | Novartis India Limited | 1368.25 | 676.49 | 97.79% | |
| IN:ASTRAZEN | AstraZeneca Pharma India Limited | 6158.50 | -2856.75 | -31.69% | |
| IN:CIPLA | Cipla Ltd | 1414.95 | -74.96 | -5.03% | |
| IN:DRREDDY | Dr. Reddy's Laboratories Ltd. | 1390.50 | 173.47 | 14.25% | |
| IN:GLENMARK | Glenmark Pharmaceuticals Limited | 2648.00 | 808.78 | 43.97% | |
| IN:LUPIN | Lupin Limited | 2010.00 | 25.69 | 1.29% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 12, 2026